Rationale and efficacy of interleukin-1 targeting in Erdheim–Chester disease
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Erdheim–Chester disease (ECD) pathophysiology remains largely unknown. Its treatment is not codified and usually disappointing. Interferon (IFN)-α therapy lacks efficacy for some life-threatening manifestations and has a poor tolerance profile. Because interleukin (IL)-1Ra synthesis is naturally induced after stimulation by IFN-α, we hypothesized that recombinant IL-1Ra (anakinra) might have some efficacy in ECD. We treated 2 patients who had poor tolerance or contraindication to IFN-α with anakinra as a rescue therapy and measured their serum C-reactive protein, IL-1β, IL-6, and monocytic membranous IL-1α (mIL-1α) levels before, under, and after therapy. Another untreated ECD patient and 5 healthy subjects were enrolled as controls. After treatment, fever and bone pains rapidly disappeared in both patients, as well as eyelid involvement in one patient. In addition, retroperitoneal fibrosis completely or partially regressed, and C-reactive protein, IL-6, and mIL-1α levels decreased to within the normal and control range. Beside injection-site reactions, no adverse event was reported. Therefore, our results support a central role of the IL-1 network, which seemed to be overstimulated in ECD. Its specific blockade using anakinra thereby opens new pathophysiology and therapeutic perspectives in ECD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Martinon, F., Burns, K., & Tschopp, J. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00599-3 · Cited by 6,066 · cited 1×
“of a NLRP3 receptor gene mutation within monocytes, leading to a greater amount of circulating IL-1β.(16,17,28-30) Although anakinra was effective, we did not observe any significant increase of IL-1β levels in our patients.”
BackgroundAgostini, L., Martinon, F., Burns, K., McDermott, M. F., Hawkins, P. N., & Tschopp, J. (2004) · Immunity · doi:10.1016/s1074-7613(04)00046-9 · Cited by 1,768 · cited 2×
“Therapy with the recombinant form of IL1Ra (anakinra) has been reported to be effective and safe in several auto-inflammatory diseases, such as cold auto-inflammatory periodic fevers and familial Mediterranean fever, in which IL1 has a pivotal role.(16-20) We successfully treated 2 ECD patients with anakinra because o…”
BackgroundOpal, S. M., & DePalo, V. A. (2000) · Chest · doi:10.1378/chest.117.4.1162 · Cited by 1,752
INTERLEUKIN-1 RECEPTOR ANTAGONIST: Role in Biology
Arend, W. P., Malyak, M., Guthridge, C. J., & Gabay, C. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.27 · Cited by 1,071
Ortiz, L. A., DuTreil, M., Fattman, C., Pandey, A. C., Torres, G., Go, K., & Phinney, D. G. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704421104 · Cited by 1,019
Cited by
A clinical perspective of IL‐1β as the gatekeeper of inflammation
Dinarello, C. A. (2011) · European Journal of Immunology · doi:10.1002/eji.201141550 · Cited by 775
Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease
Diamond, E. L., Dagna, L., Hyman, D. M., Cavalli, G., Janku, F., Estrada-Veras, J., Ferrarini, M., Abdel-Wahab, O., Heaney, M. L., Scheel, P. J., et al. (2014) · Blood · doi:10.1182/blood-2014-03-561381 · Cited by 586
Treating inflammation by blocking interleukin-1 in humans
Dinarello, C. A., & van der Meer, J. W. M. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.10.008 · Cited by 549
Arnaud, L., Hervier, B., Néel, A., Hamidou, M. A., Kahn, J.-E., Wechsler, B., Pérez-Pastor, G., Blomberg, B., Fuzibet, J.-G., Dubourguet, F., et al. (2011) · Blood · doi:10.1182/blood-2010-06-294108 · Cited by 383
Cavalli, G., Colafrancesco, S., Emmi, G., Imazio, M., Lopalco, G., Maggio, M. C., Sota, J., & Dinarello, C. A. (2021) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.102763 · Cited by 346
Metadata
- Authors
- Aouba, A., Georgin-Lavialle, S., Pagnoux, C., Martin Silva, N., Renand, A., Galateau-Salle, F., Le Toquin, S., Bensadoun, H., Larousserie, F., Silvera, S., Provost, N., Candon, S., Seror, R., de Menthon, M., Hermine, O., Guillevin, L., & Bienvenu, B.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2010-11-18
- Volume
- 116
- Issue
- 20
- Pages
- 4070-4076
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1987596886
- Cited by
- 143
- References
- 5
- FWCI
- 6.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rationale and efficacy of interleukin-1 targeting in Erdheim–Chester disease. https://app.cochat.ai/papers/10.1182/blood-2010-04-279240
- The paper
- Aouba, A., Georgin-Lavialle, S., Pagnoux, C., Martin Silva, N., Renand, A., Galateau-Salle, F., Le Toquin, S., Bensadoun, H., Larousserie, F., Silvera, S., Provost, N., Candon, S., Seror, R., de Menthon, M., Hermine, O., Guillevin, L., & Bienvenu, B. (2010). Rationale and efficacy of interleukin-1 targeting in Erdheim–Chester disease. Blood. https://doi.org/10.1182/blood-2010-04-279240
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.